3.4.22.27 (4-methyl-7-[[(2S)-2-(4-[(1S)-1-(4-methylcyclohexyl)-1-[(thiophen-3-ylcarbonyl)amino]ethyl]-1H-1,2,3-triazol-1-yl)hexanoyl]amino]-2-oxo-2H-chromen-3-yl)acetic acid + H2O - Homo sapiens ? - ? 390400 3.4.22.27 (7-methoxycoumarin-4-yl)-acetyl-GRWHPMGAPWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O specific substrate for CatS Homo sapiens (7-methoxycoumarin-4-yl)-acetyl-GRWHPMG + APWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 403056 3.4.22.27 (7-methoxycoumarin-4-yl)-acetyl-GRWPPMGLPWEK(2,4-dinitrophenyl)-D-Arg-NH2 + H2O specific substrate for CatS Homo sapiens (7-methoxycoumarin-4-yl)-acetyl-GRWPPMG + LPWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 403057 3.4.22.27 (7-[[(2S)-2-(4-[(1S)-1,2-dimethyl-1-[(phenylcarbonyl)amino]propyl]-1H-1,2,3-triazol-1-yl)hexanoyl]amino]-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid + H2O - Homo sapiens ? - ? 453089 3.4.22.27 (7-[[(2S)-2-(4-[(1S)-1,2-dimethyl-1-[(thiophen-3-ylcarbonyl)amino]propyl]-1H-1,2,3-triazol-1-yl)hexanoyl]amino]-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid + H2O - Homo sapiens ? - ? 390419 3.4.22.27 (7-[[(2S)-2-(4-[(1S)-1-cyclohexyl-1-[(phenylcarbonyl)amino]ethyl]-1H-1,2,3-triazol-1-yl)hexanoyl]amino]-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid + H2O - Homo sapiens ? - ? 390420 3.4.22.27 (7-[[(2S)-2-(4-[(1S)-1-cyclohexyl-1-[(thiophen-3-ylcarbonyl)amino]ethyl]-1H-1,2,3-triazol-1-yl)hexanoyl]amino]-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid + H2O - Homo sapiens ? - ? 390421 3.4.22.27 (benzyloxycarbonyl-Phe-Arg)2-rhodamine 110 + H2O - Homo sapiens ? - ? 362771 3.4.22.27 10 kDa fragment of the lysosomal MHCII-bound invariant chain + H2O li p10 Homo sapiens class II associated invariant chain peptide fragments - ? 390560 3.4.22.27 Ac-His-Pro-Val-Lys-7-amido-3-carbamoylmethyl-4-methylcoumarin + H2O assay at pH 5.5, 37°C Homo sapiens Ac-His-Pro-Val-Lys + 7-amino-3-carbamoylmethyl-4-methylcoumarin - ? 411539 3.4.22.27 Albumin + H2O - Homo sapiens ? - ? 16041 3.4.22.27 Albumin + H2O - Bos taurus ? - ? 16041 3.4.22.27 Albumin + H2O degradation Homo sapiens ? - ? 16041 3.4.22.27 Arg-7-amido-4-methylcoumarin + H2O - Oryctolagus cuniculus Arg + 7-amino-4-methylcoumarin - ? 361385 3.4.22.27 Arg-7-amido-4-methylcoumarin + H2O no activity detected Oryctolagus cuniculus Arg + 7-amino-4-methylcoumarin - ? 361385 3.4.22.27 arresten + H2O degradation, recombinant enzyme Homo sapiens ? - ? 384218 3.4.22.27 azocasein + H2O high activity in presence of urea at pH 5.5 Bos taurus ? - ? 15347 3.4.22.27 azocasein + H2O reaction only in presence of urea Oryctolagus cuniculus ? - ? 15347 3.4.22.27 benzoyl-Phe-Val-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus benzoyl-Phe-Val-Arg + 7-amino-4-methylcoumarin - ? 361885 3.4.22.27 benzoyl-Phe-Val-Arg-7-amido-4-methylcoumarin + H2O - Oryctolagus cuniculus benzoyl-Phe-Val-Arg + 7-amino-4-methylcoumarin - ? 361885 3.4.22.27 benzyloxycarbonyl-L-Val-L-Val-L-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus benzyloxycarbonyl-L-Val-L-Val-L-Arg + 7-amino-4-methylcoumarin - ? 384298 3.4.22.27 benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin - ? 362766 3.4.22.27 benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O - Rattus norvegicus benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin - ? 362766 3.4.22.27 benzyloxycarbonyl-Leu-Leu-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens benzyloxycarbonyl-Leu-Leu-Arg + 7-amino-4-methylcoumarin - ? 362778 3.4.22.27 benzyloxycarbonyl-Lys-4-nitrophenyl ester + H2O - Bos taurus benzyloxycarbonyl-Lys + 4-nitrophenol - ? 36943 3.4.22.27 benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin - ? 361886 3.4.22.27 benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O - Rattus norvegicus benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin - ? 361886 3.4.22.27 benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin - ? 361886 3.4.22.27 benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O - Oryctolagus cuniculus benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin - ? 361886 3.4.22.27 benzyloxycarbonyl-Phe-Val-Arg-7-amido-4-methylcoumarin - Homo sapiens benzyloxycarbonyl-Phe-Val-Arg + 7-amino-4-methylcoumarin - ? 362779 3.4.22.27 benzyloxycarbonyl-Phe-Val-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens benzyloxycarbonyl-Phe-Val-Arg + 7-amino-4-methylcoumarin - ? 391466 3.4.22.27 benzyloxycarbonyl-Val-Val-7-amido-4-methylcoumarin + H2O - Homo sapiens benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362764 3.4.22.27 benzyloxycarbonyl-Val-Val-7-amido-4-methylcoumarin + H2O - Bos taurus benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362764 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-4-methyl-coumaryl-7-amide + H2O - Rattus norvegicus benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 411722 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362763 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Rattus norvegicus benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362763 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362763 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Canis lupus familiaris benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362763 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Saimiri boliviensis benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362763 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O 73% of the activity with benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin Rattus norvegicus benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 362763 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens ? - ? 411723 3.4.22.27 benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus benzyloxycarbonyl-L-Val-L-Val-L-Arg + 7-amino-4-methylcoumarin - ? 454019 3.4.22.27 Boc-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O - Homo sapiens Boc-Val-Leu-Lys + 7-amino-4-methylcoumarin - ? 404549 3.4.22.27 butyloxycarbonyl-L-Phe-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens butyloxycarbonyl-L-Phe-L-Phe-L-Arg + 7-amino-4-methylcoumarin - ? 454020 3.4.22.27 butyloxycarbonyl-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O - Mus musculus butyloxycarbonyl-Val-Leu-Lys + 7-amino-4-methylcoumarin - ? 362303 3.4.22.27 butyloxycarbonyl-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O - Rattus norvegicus butyloxycarbonyl-Val-Leu-Lys + 7-amino-4-methylcoumarin - ? 362303 3.4.22.27 canstatin + H2O degradation, recombinant enzyme Homo sapiens ? - ? 384406 3.4.22.27 cathepsin K + H2O cathepsin S cleaves cathepsin K (cathepsin cannibalism) which reduces the total elastin- and collagen-degradative activity in the multiple cathepsin system Homo sapiens ? - ? 433541 3.4.22.27 CBZ-Val-Val-Arg- 7-amino-4-trifluoromethyl coumarin + H2O - Homo sapiens ? - ? 433547 3.4.22.27 Cbz-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens Cbz-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 404623 3.4.22.27 Collagen + H2O - Homo sapiens ? - ? 16347 3.4.22.27 Collagen + H2O - Bos taurus ? - ? 16347 3.4.22.27 Collagen + H2O - Oryctolagus cuniculus ? - ? 16347 3.4.22.27 Collagen + H2O alpha-chain Oryctolagus cuniculus ? - ? 16347 3.4.22.27 Collagen + H2O degradation Homo sapiens ? - ? 16347 3.4.22.27 Collagen type I + H2O degradation Homo sapiens ? - ? 16153 3.4.22.27 Collagen type I + H2O degradation in plasma membranes Homo sapiens ? - ? 16153 3.4.22.27 CX3CL1 + H2O cathepsin S is able to cleave membrane-anchored CX3CL1, releasing a 55-kDa fragment to the medium Homo sapiens ? - ? 432748 3.4.22.27 Elastin + H2O - Homo sapiens ? - ? 16576 3.4.22.27 Elastin + H2O can hydrolyze insoluble elastin at acid and neutral pH Bos taurus ? - ? 16576 3.4.22.27 Elastin + H2O degradation Homo sapiens ? - ? 16576 3.4.22.27 Elastin + H2O degradation in plasma membranes Homo sapiens ? - ? 16576 3.4.22.27 Elastin + H2O elastolytic enzyme activity of cathepsin S in artherosclerotic lesions, degradation of aortic elastin contributing to atherosclerosis and diabetes Homo sapiens ? - ? 16576 3.4.22.27 Elastin + H2O degradation, elastolytic enzyme activity of cathepsin S Homo sapiens ? - ? 16576 3.4.22.27 Elastin + H2O the enzyme shows distinctive preferences in degrading elastins from bovine neck ligament, aorta, and lung Homo sapiens ? - ? 16576 3.4.22.27 elastin + H2O - Mus musculus elastin fragments catS generates soluble elastin peptides ? 402619 3.4.22.27 fractalkine + H2O - Rattus norvegicus ? - ? 355704 3.4.22.27 Gelatin + H2O - Homo sapiens ? - ? 16570 3.4.22.27 Gelatin + H2O alpha-chain Oryctolagus cuniculus ? - ? 16570 3.4.22.27 GRWH-norleucine-VGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWH-norleucine-VG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405339 3.4.22.27 GRWHDVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHDVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405340 3.4.22.27 GRWHFVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHFVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405341 3.4.22.27 GRWHGVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHGVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405342 3.4.22.27 GRWHIVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHIVGL + RWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405343 3.4.22.27 GRWHKFSVRWE + H2O - Homo sapiens ? - ? 392163 3.4.22.27 GRWHKISVRWE + H2O - Homo sapiens ? - ? 392164 3.4.22.27 GRWHKLSVRWE + H2O - Homo sapiens ? - ? 392165 3.4.22.27 GRWHKVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHKVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405344 3.4.22.27 GRWHKVSVRWE + H2O - Homo sapiens GRWHKVS + VRWE - ? 392166 3.4.22.27 GRWHPVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHPVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405345 3.4.22.27 GRWHT-norleucine-GLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHT-norleucine-G + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405346 3.4.22.27 GRWHTDGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTDG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405347 3.4.22.27 GRWHTFGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTFG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405348 3.4.22.27 GRWHTGGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTGG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405349 3.4.22.27 GRWHTIGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTIG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405350 3.4.22.27 GRWHTKGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTKG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405351 3.4.22.27 GRWHTMGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTMG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405352 3.4.22.27 GRWHTPGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTPG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405353 3.4.22.27 GRWHTTGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTTG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405354 3.4.22.27 GRWHTV-norleucine-LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTV-norleucine + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405355 3.4.22.27 GRWHTVDLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVD + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405356 3.4.22.27 GRWHTVFLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVF + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405357 3.4.22.27 GRWHTVG-citrulline-RWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + citrulline-RWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405358 3.4.22.27 GRWHTVG-norleucine-RWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + norleucine-RWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405359 3.4.22.27 GRWHTVGFRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + FRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405360 3.4.22.27 GRWHTVGIRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + IRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405361 3.4.22.27 GRWHTVGKRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + KRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405362 3.4.22.27 GRWHTVGLDWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LDWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405363 3.4.22.27 GRWHTVGLFWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LFWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405364 3.4.22.27 GRWHTVGLHWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LHWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405365 3.4.22.27 GRWHTVGLIWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LIWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405366 3.4.22.27 GRWHTVGLKWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LKWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405367 3.4.22.27 GRWHTVGLPWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LPWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405368 3.4.22.27 GRWHTVGLQWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LQWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405369 3.4.22.27 GRWHTVGLRDE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRDE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405370 3.4.22.27 GRWHTVGLRFE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRFE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405371 3.4.22.27 GRWHTVGLRGE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRGE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405372 3.4.22.27 GRWHTVGLRHE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRHE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405373 3.4.22.27 GRWHTVGLRIE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRIE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405374 3.4.22.27 GRWHTVGLRKE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRKE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405375 3.4.22.27 GRWHTVGLRRE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + LRRE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405376 3.4.22.27 GRWHTVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 specific substrate for CatS Homo sapiens GRWHTVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405377 3.4.22.27 GRWHTVGRRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + RRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405378 3.4.22.27 GRWHTVGVRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVG + VRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405379 3.4.22.27 GRWHTVILRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVI + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405380 3.4.22.27 GRWHTVKLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVK + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405381 3.4.22.27 GRWHTVPLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVP + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405382 3.4.22.27 GRWHTVQLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVQ + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405383 3.4.22.27 GRWHTVTLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHTVT + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405384 3.4.22.27 GRWHVVGLRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 + H2O - Homo sapiens GRWHVVG + LRWE-Lys(2,4-dinitrophenyl)-D-Arg-NH2 - ? 405385 3.4.22.27 haemoglobin + H2O - Bos taurus ? - ? 65404 3.4.22.27 Hemoglobin + H2O - Homo sapiens ? - ? 15450 3.4.22.27 Hemoglobin + H2O degradation Homo sapiens ? - ? 15450 3.4.22.27 Ii protein + H2O - Homo sapiens Ii fragments - ? 383206 3.4.22.27 Ii protein + H2O degradation Homo sapiens Ii fragments - ? 383206 3.4.22.27 Ii protein + H2O inhibition of Ii degradation in enzyme-deficient cells leads to accumulation of Ii degradation intermediates in endosomal/lysosomal compartments Mus musculus Ii fragments - ? 383206 3.4.22.27 Ii protein + H2O Ii invariant chain Mus musculus Ii fragments - ? 383206 3.4.22.27 Ii protein + H2O inhibition of Ii degradation in enzyme-deficient cells leads to accumulation of Ii degradation intermediates in endosomal/lysosomal compartments Mus musculus C57BL/6 Ii fragments - ? 383206 3.4.22.27 Ii protein + H2O Ii invariant chain Mus musculus C57BL/6 Ii fragments - ? 383206 3.4.22.27 Ii-p10 + H2O i.e. MHC classe-associated invariant chain, cathepsin S is the only human cysteine protease able to efficiently degrade the Ii-p10 fragment in epithelial cells Homo sapiens ? - ? 362768 3.4.22.27 insulin + H2O - Homo sapiens ? - ? 36836 3.4.22.27 insulin + H2O degradation Homo sapiens ? - ? 36836 3.4.22.27 invariant chain + H2O invariant chain li is degraded by CatS to the class II-associated invariant chain peptide which dissociates from the MHC-II molecule by forming a complex with the human leucocyte antigen-DM Homo sapiens ? - ? 402714 3.4.22.27 L-Leu-Leu-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens L-Leu-Leu-Arg + 7-amino-4-methylcoumarin - ? 405613 3.4.22.27 laminin alpha5-chain + H2O the laminin-alpha5-chain is cleaved by CatS specifically at the Ser-Val bond Homo sapiens ? - ? 390248 3.4.22.27 laminin-5 + H2O degradation Mus musculus laminin-5 gamma-2 fragments - ? 383231 3.4.22.27 laminin-5 + H2O degradation Homo sapiens laminin-5 gamma-2 fragments - ? 383231 3.4.22.27 laminin-5 + H2O degradation Homo sapiens laminin-5 gamma-2 fragments bioactive gamma2-fragments of 100 kDa, 80 kDa, and 50 kDa ? 383231 3.4.22.27 laminin-5 + H2O degradation Mus musculus C57BL/6 laminin-5 gamma-2 fragments - ? 383231 3.4.22.27 leupeptin-induced peptide LIP10 + H2O - Mus musculus ? - ? 385086 3.4.22.27 MHC class II-associated invariant chain Ii + H2O degradation Mus musculus ? - ? 383246 3.4.22.27 MHC class II-associated invariant chain Ii + H2O degradation, cathepsin S and MHC class II-associated invariant chain Ii are responsible for in vivo control of endosomal size and multivesicular morphology Mus musculus ? - ? 383246 3.4.22.27 MHCII-class assosciated invariant chain li + H2O - Homo sapiens class II invariant chain peptide fragments - ? 392650 3.4.22.27 additional information - Mus musculus ? - ? 89 3.4.22.27 additional information - Homo sapiens ? - ? 89 3.4.22.27 additional information - Canis lupus familiaris ? - ? 89 3.4.22.27 additional information no activity with benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin and benzoyl-Gly-Gly-7-amido-4-methylcoumarin Oryctolagus cuniculus ? - ? 89 3.4.22.27 additional information the enzyme prefers small neutral amino acid residues in the subsites S2 and S3 Bos taurus ? - ? 89 3.4.22.27 additional information cathepsin S is implicated as a key enzyme in the processing of major histocompatability complex class II molecules Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S is implicated as a key enzyme in the processing of major histocompatability complex class II molecules Rattus norvegicus ? - ? 89 3.4.22.27 additional information primary role of the enzyme in heterophagocytosis of proteins from the ultrafiltrate Rattus norvegicus ? - ? 89 3.4.22.27 additional information cathepsin S is considered crucial for normal presentation of major histocompatibility complex class II-restricted antigens by antigen presenting cells to CD4+ T cells. It is a key enzyme for the degradation of the class II-associated invariant chain, a process that is required for effective antigen loading of class II molecules Homo sapiens ? - ? 89 3.4.22.27 additional information the enzyme may contribute to the contact-dependent elastase activity of live human alveolar macrophages Homo sapiens ? - ? 89 3.4.22.27 additional information key protease responsible for the removal of the invariant chain from MHC class II molecules, the enzyme plays a major role in antigen presentation Canis lupus familiaris ? - ? 89 3.4.22.27 additional information key protease responsible for the removal of the invariant chain from MHC class II molecules, the enzyme plays a major role in antigen presentation Saimiri boliviensis ? - ? 89 3.4.22.27 additional information cathepsin S is possibly involved in thyroid hormone biosynthesis Rattus norvegicus ? - ? 89 3.4.22.27 additional information Cat S is involved in degradtion of extracellular matrix and smooth muscle cell invasion, but not in adhesion and migration, overview, the enzyme shows elastolytic and collagenolytic activities on smooth muscle cell plasma membranes, overview Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsin S catalyzes a key step in antigen presentation, detailed overview Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S catalyzes a key step in antigen presentation, detailed overview Rattus norvegicus ? - ? 89 3.4.22.27 additional information cathepsin S catalyzes a key step in antigen presentation, detailed overview Bos taurus ? - ? 89 3.4.22.27 additional information cathepsin S catalyzes a key step in antigen presentation, detailed overview, Cat S might be involved in psoriasis induction due to an increased interferon gamma level in the epidermis, Cat S is increased in neurons of Alzheimer's disease and Down's syndrome patients, where Cat S facilitates the formation of amyloidbeta from its precursor protein, Cat S might also be involved in asthma, Sjörgren's syndrome, allergen-specific T-cell proliferation in autoimmune processes, and atherosclerosis, overview Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors, the enzyme is required for neoplastic progression, overview Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors, the enzyme is required for neoplastic progression, overview Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsin S in professional antigen-presenting cells, APC, controls MHC class II-mediated antigen presentation by epithelial cells in vivo, and plays a critical role in invariant chain degradation Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S is responsible for murine autoimmune myasthenia gravis pathogenesis, overview Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S, a cysteine protease, plays an important role in generating peptides for the vacuolar, TAP-independent MHC class I cross-presentation in vivo Mus musculus ? - ? 89 3.4.22.27 additional information serum cathepsin S is increased in patients with atherosclerosis and diabetes, the cystatin C level might play a role in disease development, overview Homo sapiens ? - ? 89 3.4.22.27 additional information the enzyme is involved in obesity and development of adiposity, enzyme regulation in subcutaneous adipose tissue, cathepsin S is upregulated in obesity, overview Homo sapiens ? - ? 89 3.4.22.27 additional information active Cat S co-localizes with integrins, e.g. integrin alphanubeta3 Homo sapiens ? - ? 89 3.4.22.27 additional information Cat S forms an alpha-beta-CLIP complex, unlike CatB or CatD, from an alpha-beta-Ii molecule in vitro Mus musculus ? - ? 89 3.4.22.27 additional information Cat S forms an alpha-beta-CLIP complex, unlike CatB or CatD, from an alpha-beta-Ii molecule in vitro Homo sapiens ? - ? 89 3.4.22.27 additional information does not cleave GRWHKISVRWE Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S is an elastolytic enzyme Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S is putatively involved in the pathogenesis of COPD Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsins are primarily involved in general protein turnover, CATS belongs to the cathepsins with a distinct substrate specificity Mus musculus ? - ? 89 3.4.22.27 additional information catS has proinflammatory effects Mus musculus ? - ? 89 3.4.22.27 additional information catS is a potent elastolytic protease and accelerates calcification in atherosclerotic mice with chronic renal disease induced by 5/6 nephrectemy Mus musculus ? - ? 89 3.4.22.27 additional information CATS is an important player in the spinal mechanisms involved in chronic pain induction and maintenance Rattus norvegicus ? - ? 89 3.4.22.27 additional information CatS is capable of degrading a range of extracellular matrix macromolecules Homo sapiens ? - ? 89 3.4.22.27 additional information CatS is identified as a compound involved in MHC class II maturation and trafficking within antigen presentation pathways, as well as in the control of processing antigens and the formation of peptide-receptive class II dimers Homo sapiens ? - ? 89 3.4.22.27 additional information CatS is implicated in the regulation of intracellular cholesterol metabolism Mus musculus ? - ? 89 3.4.22.27 additional information CatS is one of the major proteases involved in antigen processing Homo sapiens ? - ? 89 3.4.22.27 additional information CATS is widely expressed in the brain and is implicated in several neurological conditions such as Alzheimer's disease, amyotrophic lateral sclerosis and age-related inflammation, CATS is also implicated in neuropathic hyperalgesia and allodynia Rattus norvegicus ? - ? 89 3.4.22.27 additional information CATS participates in inflammatory processes accompanying aging and pathologies of the central nervous system Mus musculus ? - ? 89 3.4.22.27 additional information CTSS is a cysteine protease that has a central role in remodeling the extracellular matrix and it is implicated in the etiology of cardiovascular disease Homo sapiens ? - ? 89 3.4.22.27 additional information enzyme mediates degradation of the MHC class II invariant chain and participates in antigen processing Homo sapiens ? - ? 89 3.4.22.27 additional information in antigen presenting cells Cat S plays an essential role in the proteolytic events that lead to antigen presentation at the cells surface for recognition by T cells Homo sapiens ? - ? 89 3.4.22.27 additional information in the case of atherosclerotic lesions, the local extracellular matrix is degraded either by CatS secreted by smooth muscle cells and macrophages or by circulating CatS produced by adipose tissue, this elastolytic activity of CatS causes the migration of blood monocytes and smooth muscle cells into the vascular wall which leads to the progression of atherosclerotic lesions Homo sapiens ? - ? 89 3.4.22.27 additional information it degrades the invariant chain Ii, which is crucial to the immune response since it acts as an essential step in MHC class II antigen presentation Mus musculus ? - ? 89 3.4.22.27 additional information major role of Cat S in these cells is the processing of the major histocompatibility complex class II associated invariant chain, which is essential for the normal functioning of the immune system, Cat S is largely responsible for the last proteolytic cleavage step of the invariant chain that produces class II-associated leupeptin induced peptide Homo sapiens ? - ? 89 3.4.22.27 additional information protease is implicated in the development of atherosclerotic lesions in both animal Homo sapiens ? - ? 89 3.4.22.27 additional information proteolysis of prion protein by cathepsin S generates a soluble-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms Ovis aries ? - ? 89 3.4.22.27 additional information the cysteine protease cathepsin S is involved in the pathogenesis of autoimmune disorders, atherosclerosis and obesity Homo sapiens ? - ? 89 3.4.22.27 additional information the function of cathepsin S within antigen presenting cells relates to its pivotal role in major histocompatibility class II restricted antigen presentation to CD4+ T-lymphocytes, cathepsin S mediates the final proteolytic cleavage of the invariant chain chaperone molecule 2 thereby facilitating the subsequent presentation of MHC-II associated peptides to CD4+ T-cells Homo sapiens ? - ? 89 3.4.22.27 additional information the major role of CAT S is the processing of the major histocompatibility complex (MHC) class II associated invariant chain, which is essential for the normal functioning of the immune system Homo sapiens ? - ? 89 3.4.22.27 additional information this enzyme serves a crucial role in MHC class II mediated immune systems, resulting in CD4+ T cell activation Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsin S substrate Leu-Arg and a poly(ethylene glycol) chain in dendritic arms Mus musculus ? - ? 89 3.4.22.27 additional information cathepsin S-dependent activation of PAR-2 activation Homo sapiens ? - ? 89 3.4.22.27 additional information cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors, the enzyme is required for neoplastic progression, overview Mus musculus C57BL/6 ? - ? 89 3.4.22.27 additional information cathepsin S in professional antigen-presenting cells, APC, controls MHC class II-mediated antigen presentation by epithelial cells in vivo, and plays a critical role in invariant chain degradation Mus musculus C57BL/6 ? - ? 89 3.4.22.27 additional information cathepsin S is responsible for murine autoimmune myasthenia gravis pathogenesis, overview Mus musculus C57BL/6 ? - ? 89 3.4.22.27 myelin basic protein + H2O - Homo sapiens ? - ? 140925 3.4.22.27 myelin basic protein + H2O degradation Homo sapiens ? - ? 140925 3.4.22.27 N-benzyloxycarbonyl-L-Phe-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens N-benzyloxycarbonyl-L-Phe-Arg + 7-amino-4-methylcoumarin - ? 412518 3.4.22.27 N-benzyloxycarbonyl-Phe-Arg-4-nitroanilide + H2O - Sciaenops ocellatus N-benzyloxycarbonyl-Phe-Arg + 4-nitroaniline - ? 450359 3.4.22.27 N-[(1S)-1-[1-[(1S)-1-cyanopentyl]-1H-1,2,3-triazol-4-yl]-1,2-dimethylpropyl]benzamide + H2O - Homo sapiens ? - ? 392835 3.4.22.27 o-aminobenzoic acid-Ala-Thr-Pro-Leu-Leu-Met-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Ala-Thr-Pro-Leu-Leu + Met-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) 80% cleavage site, 20% cleavage site: o-aminobenzoic acid-Ala-Thr-Pro-Leu-Leu-Met + Gln-(N-[2,4-dinitrophenyl]ethylenediamine) ? 412608 3.4.22.27 o-aminobenzoic acid-Gly-Arg-Leu-Asp-Lys-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Gly-Arg-Leu-Asp + Lys-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) - ? 412609 3.4.22.27 o-aminobenzoic acid-Gly-Phe-Phe-Val-Thr-Thr-Pro-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Gly-Phe-Phe + Val-Thr-Thr-Pro-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) - ? 412610 3.4.22.27 o-aminobenzoic acid-His-Leu-Val-Glu-Ala-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-His-Leu-Val-Glu + Ala-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) - ? 412611 3.4.22.27 o-aminobenzoic acid-His-Leu-Val-Glu-Ala-Leu-Tyr-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-His-Leu-Val-Glu + Ala-Leu-Tyr-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) 56% cleavage site, 44% cleavage site: o-aminobenzoic acid-His-Leu-Val-Glu-Ala-Leu + Tyr-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) ? 412612 3.4.22.27 o-aminobenzoic acid-Leu-Arg-Met-Lys-Leu-Pro-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Leu-Arg-Met-Lys + Leu-Pro-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) 74% cleavage site, 26% cleavage site: o-aminobenzoic acid-Leu-Arg + Met-Lys-Leu-Pro-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) ? 412613 3.4.22.27 o-aminobenzoic acid-Leu-Gln-Leu-Glu-Asn-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Leu-Gln + Leu-Glu-Asn-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) 57% cleavage site, 42% cleavage site: o-aminobenzoic acid-Leu-Gln-Leu-Glu + Asn-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) ? 412614 3.4.22.27 o-aminobenzoic acid-Leu-Glu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Leu-Glu + Gln-(N-[2,4-dinitrophenyl]ethylenediamine) - ? 412615 3.4.22.27 o-aminobenzoic acid-Leu-Phe-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylendiamine + H2O - Homo sapiens o-aminobenzoic acid-Leu-Phe + Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylendiamine - ? 412616 3.4.22.27 o-aminobenzoic acid-Leu-Tyr-Leu-Val-Cys-Gly-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Leu-Tyr-Leu + Val-Cys-Gly-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) 70% cleavage site, 30% cleavage site: o-aminobenzoic acid-Leu-Tyr + Leu-Val-Cys-Gly-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) ? 412617 3.4.22.27 o-aminobenzoic acid-Lys-Pro-Pro-Val-Val-Leu-Leu-Pro-Asp-Gln-N-(2,4-dinitrophenyl)ethylendiamine + H2O - Homo sapiens o-aminobenzoic acid-Lys-Pro-Pro-Val-Val-Leu + Leu-Pro-Asp-Gln-N-(2,4-dinitrophenyl)ethylendiamine - ? 412618 3.4.22.27 o-aminobenzoic acid-Lys-Pro-Val-Ser-Thr-Glu-Gln-Leu-Ala-Gln-N-(2,4-dinitrophenyl)ethylendiamine + H2O - Homo sapiens o-aminobenzoic acid-Lys-Pro-Val-Ser + Thr-Glu-Gln-Leu-Ala-Gln-N-(2,4-dinitrophenyl)ethylendiamine - ? 412619 3.4.22.27 o-aminobenzoic acid-Phe-Val-Asn-Gln-His-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Phe-Val-Asn + Gln-His-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) 69% cleavage site, 31% cleavage site: o-aminobenzoic acid-Glu-Val + Asn-Gln-His-Leu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) ? 412620 3.4.22.27 o-aminobenzoic acid-Ser-Arg-His-Ser-Leu-Glu-Gln-(N-[2,4-dinitrophenyl]ethylenediamine) + H2O - Homo sapiens o-aminobenzoic acid-Ser-Arg-His-Ser-Leu-Glu + Gln-(N-[2,4-dinitrophenyl]ethylenediamine) - ? 412621 3.4.22.27 o-aminobenzoic acid-Val-Leu-Phe-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylendiamine + H2O - Homo sapiens o-aminobenzoic acid-Val-Leu-Phe + Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylendiamine - ? 412622 3.4.22.27 o-aminobenzoic acid-Val-Leu-Phe-Glu-Lys-Lys-Val-Tyr-Leu-Gln-N-(2,4-dinitrophenyl)ethylendiamine + H2O - Homo sapiens o-aminobenzoic acid-Val-Leu-Phe-Glu-Lys-Lys-Val-Tyr + Leu-Gln-N-(2,4-dinitrophenyl)ethylendiamine - ? 412623 3.4.22.27 Oxidized insulin B-chain + H2O major cleavage sites: Glu13-Ala14, Leu17-Val18 and Phe25-Tyr26. Minor cleavage sites: Asn3-Gln4, Ser9-His10 and Leu15-Tyr16 Bos taurus ? - ? 15443 3.4.22.27 plasminogen + H2O - Homo sapiens ? cleavage occurs at the Leu469-Leu470 peptide bond resulting in 2 fragments: 60000 Da and 38000 Da ? 74447 3.4.22.27 prion protein 94-233 + H2O in vitro, enzyme causes specific and limited N-terminal truncation of prion protein 94-233 Ovis aries prion protein 135-233 + prion protein 117-233 + prion protein 114-233 major soluble fragments, the region of prion protein between S135 and N146 is a major target for selective cleavage cathepsins S ? 402857 3.4.22.27 pro-dipeptidyl peptidase I + H2O i.e. cathepsin C, less efficient activation than with cathepsin L Homo sapiens ? - ? 362769 3.4.22.27 protease-activated receptor-2 + H2O - Mus musculus ? - ? 394057 3.4.22.27 protease-activated receptor-2 + H2O - Homo sapiens ? - ? 394057 3.4.22.27 tert-butyloxycarbonyl-Phe-Leu-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus tert-butyloxycarbonyl-Phe-Leu-Arg + 7-amino-4-methylcoumarin - ? 362776 3.4.22.27 tert-butyloxycarbonyl-Phe-Phe-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens tert-butyloxycarbonyl-Phe-Phe-Arg + 7-amino-4-methylcoumarin - ? 362775 3.4.22.27 tert-butyloxycarbonyl-Phe-Phe-Arg-7-amido-4-methylcoumarin + H2O - Bos taurus tert-butyloxycarbonyl-Phe-Phe-Arg + 7-amino-4-methylcoumarin - ? 362775 3.4.22.27 Val-Arg-coumarin + H2O - Homo sapiens ? - ? 362767 3.4.22.27 Val-Val-Arg + H2O - Homo sapiens ? - ? 402974 3.4.22.27 Z-Leu-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens Z-Leu-Arg + 7-amino-4-methylcoumarin - ? 385963 3.4.22.27 Z-Leu-Leu-Arg-7-amido-4-methylcoumarin + H2O - Mus musculus Z-Leu-Leu-Arg + 7-amino-4-methylcoumarin - ? 406911 3.4.22.27 Z-Leu-Leu-Arg-7-amido-4-methylcoumarin + H2O - Homo sapiens Z-Leu-Leu-Arg + 7-amino-4-methylcoumarin - ? 406911 3.4.22.27 Z-Leu-Leu-Arg-7-amido-4-methylcoumarin + H2O - Rattus norvegicus Z-Leu-Leu-Arg + 7-amino-4-methylcoumarin - ? 406911 3.4.22.27 Z-Phe-Arg-AMC + H2O - Paralichthys olivaceus ? - ? 419209 3.4.22.27 Z-Val-Val-Arg-7-amido-4-methylcoumarin + H2O - Mus musculus Z-Val-Val-Arg + 7-amino-4-methylcoumarin - ? 406915 3.4.22.27 Z-Val-Val-Arg-AMC + H2O - Paralichthys olivaceus ? - ? 419210